The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest ...
The Inflation Reduction Act (the Act) of 2022 was controversial at the time the Act was signed into law and remains so. To date, multiple ...
The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse ...
The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to increase oversight of the Medicare Advantage and ...
A record-low number of Medicare Part D plans could cause greater Medicare Advantage enrollment, which may not be a good thing ...
With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.
Proposal would let patients get Wegovy, Ozempic, related drugs for obesity, which is not a covered condition now.
The panel focused on the provisions of the Inflation Reduction Act that aim to lower prescription drug prices under Medicare.
The Centers for Medicare & Medicaid Services is attempting to cover anti-obesity medications under Medicare Part D and ...
Seniors in metro Detroit and across Michigan have an opportunity to sign up for the right Medicare plan during open ...
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback